Free Trial

Femasys (FEMY) Competitors

Femasys logo
$0.93 -0.02 (-1.66%)
As of 07/3/2025 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FEMY vs. SLNO, FONR, MBOT, NTRB, APYX, GUTS, SRTS, VANI, TELA, and INO

Should you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), Fonar (FONR), Microbot Medical (MBOT), Nutriband (NTRB), Apyx Medical (APYX), Fractyl Health (GUTS), Sensus Healthcare (SRTS), Vivani Medical (VANI), TELA Bio (TELA), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry.

Femasys vs. Its Competitors

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Soleno Therapeutics had 4 more articles in the media than Femasys. MarketBeat recorded 7 mentions for Soleno Therapeutics and 3 mentions for Femasys. Femasys' average media sentiment score of 0.92 beat Soleno Therapeutics' score of 0.86 indicating that Femasys is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Soleno Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Femasys
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Soleno Therapeutics currently has a consensus target price of $107.10, indicating a potential upside of 23.62%. Femasys has a consensus target price of $8.67, indicating a potential upside of 827.91%. Given Femasys' higher probable upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.09
Femasys
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A-$175.85M-$4.62-18.75
Femasys$1.63M14.64-$18.82M-$0.91-1.03

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 11.5% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. Soleno Therapeutics' return on equity of -77.52% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Soleno TherapeuticsN/A -77.52% -63.44%
Femasys -1,242.06%-392.45%-137.15%

Soleno Therapeutics has a beta of -2.63, suggesting that its share price is 363% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.56, suggesting that its share price is 356% less volatile than the S&P 500.

Summary

Soleno Therapeutics and Femasys tied by winning 8 of the 16 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FEMY vs. The Competition

MetricFemasysMED IndustryMedical SectorNASDAQ Exchange
Market Cap$23.80M$2.91B$5.56B$9.03B
Dividend YieldN/A2.44%5.22%3.99%
P/E Ratio-1.0321.5627.6920.25
Price / Sales14.64246.41389.63163.10
Price / CashN/A42.7336.8958.10
Price / Book9.347.518.035.67
Net Income-$18.82M-$55.14M$3.18B$249.21M
7 Day Performance-4.69%4.61%2.93%3.28%
1 Month Performance16.75%0.90%1.72%3.95%
1 Year Performance-15.86%5.40%34.39%20.98%

Femasys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FEMY
Femasys
3.8477 of 5 stars
$0.93
-1.7%
$8.67
+827.9%
-15.9%$23.80M$1.63M-1.0330
SLNO
Soleno Therapeutics
4.4462 of 5 stars
$83.78
+0.6%
$107.10
+27.8%
+111.8%$4.20BN/A-18.1330News Coverage
Insider Trade
FONR
Fonar
1.2508 of 5 stars
$14.96
+0.5%
N/A-4.2%$92.31M$102.88M11.97480News Coverage
Positive News
MBOT
Microbot Medical
1.9791 of 5 stars
$2.52
+0.8%
$9.00
+257.1%
+144.1%$90.94MN/A-3.8820
NTRB
Nutriband
3.2314 of 5 stars
$7.87
-1.4%
$13.00
+65.2%
+66.2%$89.01M$2.14M-8.7410News Coverage
APYX
Apyx Medical
2.3506 of 5 stars
$2.25
+4.2%
N/A+66.2%$81.64M$48.10M-4.09270
GUTS
Fractyl Health
2.0258 of 5 stars
$1.62
-1.2%
$11.00
+579.0%
-63.2%$80.32M$90K-0.88102
SRTS
Sensus Healthcare
1.5167 of 5 stars
$4.74
-2.5%
$11.67
+146.1%
-9.2%$79.92M$39.49M47.4040
VANI
Vivani Medical
2.8122 of 5 stars
$1.29
-2.3%
$4.00
+210.1%
+4.1%$78.20MN/A-3.0020
TELA
TELA Bio
2.5772 of 5 stars
$1.94
-1.5%
$7.25
+273.7%
-52.6%$77.92M$69.30M-1.38120Gap Up
INO
Inovio Pharmaceuticals
3.8591 of 5 stars
$2.04
-3.3%
$9.75
+377.9%
-83.9%$77.38M$220K-0.64320News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:FEMY) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners